Isu Abxis Obtains Chinese Patent for Anticancer Drug Candidate
[Asia Economy Reporter Seongpil Cho] ISU Abxis announced on the 25th that it has obtained a patent in China for its anticancer drug candidate 'ISU104' (generic name: varecetumab). This is the seventh patent acquired after registrations in six countries. The patent pertains to an antibody that specifically binds to ErbB3 for the treatment of cancers in which the ErbB3 protein is activated or overexpressed and that are resistant to anticancer drugs inhibiting ErbB1 or ErbB2.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
